文献速递肿瘤 PET/CT甲状腺核医学

进展性转移性甲状腺髓样癌患者单一个体中18F-FDG、68Ga-DOTATATE与68Ga-DOTA-FAPi-04 PET/CT显像的示踪剂亲和力变异及病灶间异质性

Variable Tracer Avidity and Interlesional Heterogeneity on 18 F-FDG, 68 Ga-DOTATATE, and 68 Ga-DOTA-FAPi-04 PET/CT Imaging in a Single Individual Patient With Progressive Metastatic Medullary Thyroid Carcinoma.
PubMed 文献 · Clin Nucl Med · 2024-10-03

本文报道一例进展性转移性甲状腺髓样癌(MTC)患者,在18F-FDG、68Ga-DOTATATE和68Ga-DOTA-FAPI-04三种PET/CT显像中呈现示踪剂亲和力变异及病灶间异质性。68Ga-DOTA-FAPI-04 PET/CT在转移性软组织、淋巴结和骨骼病灶的可视化方面优于另外两种显像,靶本比更高,有助于这些病灶的检测,显示出诊疗一体化的潜力。

要点

  • MTC远处转移治疗选择少、成功率低且毒性大,需探索不良反应更少的替代全身治疗。
  • 68Ga-DOTA-FAPI-04 PET/CT对转移性软组织、淋巴结和骨骼病灶的可视化优于18F-FDG和68Ga-DOTATATE。
  • 同一患者不同病灶对三种示踪剂的亲和力存在异质性,FAPI显像显示诊疗一体化潜力。

核心结论

  • 68Ga-DOTA-FAPI-04 PET/CT在转移性软组织、淋巴结和骨骼病灶的可视化方面优于18F-FDG和68Ga-DOTATATE,靶本比更高,有助于检测这些病灶,显示出诊疗一体化的潜力。

研究设计与样本

  • 本文为单一个体进展性转移性甲状腺髓样癌患者的病例报告,比较18F-FDG、68Ga-DOTATATE和68Ga-DOTA-FAPI-04三种PET/CT显像。

主要发现

  • 同一患者不同病灶对18F-FDG、68Ga-DOTATATE和68Ga-DOTA-FAPI-04的亲和力存在变异及病灶间异质性。
  • 68Ga-DOTA-FAPI-04 PET/CT在转移性软组织、淋巴结和骨骼病灶的可视化方面优于另外两种显像,靶本比更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In medullary thyroid carcinoma (MTC), distant metastases have few therapeutic options with low success rates and substantial toxicity in many patients, warranting exploration of alternate systemic treatments with fewer adverse effects. The fibroblast activation protein inhibitor (FAPI)-based PET/CT opens new avenues for several cancers, including MTC. A case of MTC with varying tracer avidity and interlesional heterogeneity on 18 F-FDG, 68 Ga-DOTATATE, and 68 Ga-DOTA-FAPI-04 PET/CT imaging is presented. 68 Ga-DOTA-FAPI-04 PET/CT exhibited superior efficacy in terms of visualization of metastatic soft tissue, lymph nodal, and skeletal lesions, with enhanced target-to-background ratio compared with the other two, facilitating the detection of these lesions, thereby demonstrating the potential for theranostic translation.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Edamadaka Y, Parghane RV, Basu S, et al. Variable Tracer Avidity and Interlesional Heterogeneity on 18 F-FDG, 68 Ga-DOTATATE, and 68 Ga-DOTA-FAPi-04 PET/CT Imaging in a Single Individual Patient With Progressive Metastatic Medullary Thyroid Carcinoma. Clin Nucl Med. 2024. PMID: 39365099. doi:10.1097/RLU.0000000000005469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。